Agile Therapeutics Analyst Ratings
Agile Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Agile Therapeutics (AGRX) rating was a maintained with a price target of $5.00 to $3.00. The current price Agile Therapeutics (AGRX) is trading at is $0.20, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/30/2022 | 1403.76% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 07/26/2022 | 401.25% | Maxim Group | → $1 | Upgrades | Hold → Buy |
| 07/11/2022 | 2406.27% | HC Wainwright & Co. | $2.5 → $5 | Maintains | Buy |
| 04/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/03/2021 | 1153.13% | HC Wainwright & Co. | $3.5 → $2.5 | Maintains | Buy |
| 09/13/2021 | 1654.39% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 07/27/2021 | 2406.27% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 12/08/2020 | 3408.77% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/20/2020 | 2907.52% | HC Wainwright & Co. | $7 → $6 | Reiterates | → Buy |
| 02/18/2020 | 3408.77% | HC Wainwright & Co. | $5 → $7 | Maintains | Buy |
| 02/18/2020 | 3910.03% | RBC Capital | $5 → $8 | Maintains | Outperform |
| 06/07/2019 | 2406.27% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 11/29/2018 | 1403.76% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2022年12月30日 | 1403.76% | HC Wainwright公司 | $5→$3 | 維護 | 買 |
| 07/26/2022 | 401.25% | Maxim集團 | →$1 | 升級 | 持有→購買 |
| 07/11/2022 | 2406.27% | HC Wainwright公司 | $2.5→$5 | 維護 | 買 |
| 04/08/2022 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 11/03/2021 | 1153.13% | HC Wainwright公司 | $3.5→$2.5 | 維護 | 買 |
| 09/13/2021 | 1654.39% | HC Wainwright公司 | $7→$3.5 | 維護 | 買 |
| 07/27/2021 | 2406.27% | 加拿大皇家銀行資本 | $6→$5 | 維護 | 跑贏大盤 |
| 12/08/2020 | 3408.77% | HC Wainwright公司 | $6→$7 | 維護 | 買 |
| 03/20/2020 | 2907.52% | HC Wainwright公司 | $7→$6 | 重申 | →購買 |
| 02/18/2020 | 3408.77% | HC Wainwright公司 | $5→$7 | 維護 | 買 |
| 02/18/2020 | 3910.03% | 加拿大皇家銀行資本 | $5→$8 | 維護 | 跑贏大盤 |
| 2019年07月06日 | 2406.27% | 奧本海默 | →$5 | 開始承保 | →跑贏大盤 |
| 2018年11月29日 | 1403.76% | Maxim集團 | →$3 | 開始承保 | →購買 |
What is the target price for Agile Therapeutics (AGRX)?
雅居樂治療(AGRX)的目標價格是多少？
The latest price target for Agile Therapeutics (NASDAQ: AGRX) was reported by HC Wainwright & Co. on December 30, 2022. The analyst firm set a price target for $3.00 expecting AGRX to rise to within 12 months (a possible 1403.76% upside). 4 analyst firms have reported ratings in the last year.
2022年12月30日，HC Wainwright&Co.報道了雅居樂治療公司(納斯達克：AGRX)的最新目標價。這家分析公司將目標價定為3美元，預計AGRX將在12個月內上漲至(可能上漲1403.76%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Agile Therapeutics (AGRX)?
雅居樂治療公司(AGRX)的最新分析師評級是什麼？
The latest analyst rating for Agile Therapeutics (NASDAQ: AGRX) was provided by HC Wainwright & Co., and Agile Therapeutics maintained their buy rating.
雅居樂治療公司(納斯達克代碼：AGRX)的最新分析師評級由HC Wainwright&Co.提供，雅居樂治療公司維持買入評級。
When is the next analyst rating going to be posted or updated for Agile Therapeutics (AGRX)?
雅居樂治療公司(AGRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics was filed on December 30, 2022 so you should expect the next rating to be made available sometime around December 30, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與雅居樂治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。雅居樂治療公司的上一次評級是在2022年12月30日提交的，所以你應該預計下一次評級將在2023年12月30日左右的某個時候提供。
Is the Analyst Rating Agile Therapeutics (AGRX) correct?
分析師對Agile Treeutics(AGRX)的評級正確嗎？
While ratings are subjective and will change, the latest Agile Therapeutics (AGRX) rating was a maintained with a price target of $5.00 to $3.00. The current price Agile Therapeutics (AGRX) is trading at is $0.20, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的雅居樂治療(AGRX)評級保持不變，目標價在5.00美元至3.00美元之間。雅居樂治療公司(Agile Treateutics)目前的交易價格為0.20美元，超出了分析師的預測區間。